Literature DB >> 19834274

Paraneoplastic nephrotic syndrome in patients with lung cancer.

Gen Ohara1, Hiroaki Satoh, Koichi Kurishima, Morio Ohtsuka, Nobuyuki Hizawa.   

Abstract

Paraneoplastic nephrotic syndrome has been reported in various malignancies: malignant lymphoma, colon cancer, lung cancer, and prostate cancer. Of these, lung cancer is the most commonly associated with the syndrome. Here, we report 4 cases of nephrotic syndrome associated with lung cancer, in one of which urinary protein and edema were improved by steroid therapy. These results suggest that in patients with paraneoplastic nephrotic syndrome histologically diagnosed as having minimal change disease (MCD), it is important not only to treat the cancer itself but also to use steroids as early as possible. On the other hand, our results also showed that treatment is still difficult for locally advanced or metastatic tumors. Therefore, when we encounter patients with nephrotic syndrome, it is important to be aware of the association of nephrotic syndrome and lung cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19834274     DOI: 10.2169/internalmedicine.48.2089

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

Review 1.  Paraneoplastic syndromes associated with lung cancer.

Authors:  Nobuhiro Kanaji; Naoki Watanabe; Nobuyuki Kita; Shuji Bandoh; Akira Tadokoro; Tomoya Ishii; Hiroaki Dobashi; Takuya Matsunaga
Journal:  World J Clin Oncol       Date:  2014-08-10

2.  Recurrence of paraneoplastic membranous glomerulonephritis following chemoradiation in a man with non-small-cell lung carcinoma.

Authors:  Andrew R Crawford; Lance Dworkin; Kara Leonard; Humera Khurshid; Jaroslaw T Hepel
Journal:  Rare Tumors       Date:  2013-05-06

3.  Primary lung cancer firstly presents as nephrotic syndrome: one case report and literature review.

Authors:  Dongmei Gu; Wenjie Liao; Qingqing Su; Jie Gu; Yanbin Chen
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.